

Michael McClung

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6141056/publications.pdf>

Version: 2024-02-01

204
papers

24,345
citations

8749

75
h-index

7152

153
g-index

236
all docs

236
docs citations

236
times ranked

12592
citing authors

#	ARTICLE	IF	CITATIONS
1	Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis. <i>New England Journal of Medicine</i> , 2009, 361, 756-765.	13.9	2,747
2	Effect of Risedronate on the Risk of Hip Fracture in Elderly Women. <i>New England Journal of Medicine</i> , 2001, 344, 333-340.	13.9	1,831
3	Osteoporosis. <i>Lancet, The</i> , 2019, 393, 364-376.	6.3	1,252
4	Denosumab in Postmenopausal Women with Low Bone Mineral Density. <i>New England Journal of Medicine</i> , 2006, 354, 821-831.	13.9	1,107
5	Romosozumab in Postmenopausal Women with Low Bone Mineral Density. <i>New England Journal of Medicine</i> , 2014, 370, 412-420.	13.9	981
6	Parathyroid Hormone and Teriparatide for the Treatment of Osteoporosis: A Review of the Evidence and Suggested Guidelines for Its Use. <i>Endocrine Reviews</i> , 2005, 26, 688-703.	8.9	630
7	Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial. <i>Bone</i> , 2008, 43, 222-229.	1.4	495
8	Prevention of Bone Loss with Alendronate in Postmenopausal Women under 60 Years of Age. <i>New England Journal of Medicine</i> , 1998, 338, 485-492.	13.9	493
9	American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis—2020 Update. <i>Endocrine Practice</i> , 2020, 26, 1-46.	1.1	493
10	Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 190-198.	3.1	474
11	Bisphosphonate Therapy for Osteoporosis: Benefits, Risks, and Drug Holiday. <i>American Journal of Medicine</i> , 2013, 126, 13-20.	0.6	408
12	American Association of Clinical Endocrinologists Medical Guidelines For Clinical Practice For The Prevention and Treatment of Postmenopausal Osteoporosis: 2001 Edition, With Selected Updates For 2003. <i>Endocrine Practice</i> , 2003, 9, 544-564.	1.1	390
13	Opposite Bone Remodeling Effects of Teriparatide and Alendronate in Increasing Bone Mass. <i>Archives of Internal Medicine</i> , 2005, 165, 1762.	4.3	385
14	Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling. <i>American Journal of Medicine</i> , 1995, 99, 144-152.	0.6	340
15	American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Postmenopausal Osteoporosis. <i>Endocrine Practice</i> , 2010, 16, 1-37.	1.1	331
16	The Efficacy and Tolerability of Risedronate Once a week for the Treatment of Postmenopausal Osteoporosis. <i>Calcified Tissue International</i> , 2002, 71, 103-111.	1.5	307
17	Treatment With Once-Weekly Alendronate 70 mg Compared With Once-Weekly Risedronate 35 mg in Women With Postmenopausal Osteoporosis: A Randomized Double-Blind Study. <i>Journal of Bone and Mineral Research</i> , 2005, 20, 141-151.	3.1	291
18	Monthly Oral Ibandronate Therapy in Postmenopausal Osteoporosis: 1-Year Results From the MOBILE Study. <i>Journal of Bone and Mineral Research</i> , 2005, 20, 1315-1322.	3.1	288

#	ARTICLE	IF	CITATIONS
19	Two-Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD. <i>Journal of Bone and Mineral Research</i> , 2007, 22, 1832-1841.	3.1	282
20	Effects of denosumab on fracture and bone mineral density by level of kidney function. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 1829-1835.	3.1	282
21	Odanacatib, a cathepsin-K inhibitor for osteoporosis: A two-year study in postmenopausal women with low bone density. <i>Journal of Bone and Mineral Research</i> , 2010, 25, 937-947.	3.1	269
22	Official Positions of the International Society for Clinical Densitometry. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 3651-3655.	1.8	242
23	Alendronate Prevents Postmenopausal Bone Loss in Women without Osteoporosis: A Double-Blind, Randomized, Controlled Trial. <i>Annals of Internal Medicine</i> , 1998, 128, 253.	2.0	233
24	Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three-year continued therapy and resolution of effect. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 242-251.	3.1	220
25	The Rate of Bone Mineral Loss in Normal Men and the Effects of Calcium and Cholecalciferol Supplementation. <i>Annals of Internal Medicine</i> , 1990, 112, 29.	2.0	212
26	Fracture risk remains reduced one year after discontinuation of risedronate. <i>Osteoporosis International</i> , 2008, 19, 365-372.	1.3	206
27	Vertebral Fractures: Clinical Importance and Management. <i>American Journal of Medicine</i> , 2016, 129, 221.e1-221.e10.	0.6	204
28	Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 530-537.	3.1	188
29	Diagnosis and management of osteoporosis in postmenopausal women: Clinical guidelines. <i>Clinical Therapeutics</i> , 1999, 21, 1025-1044.	1.1	187
30	A Randomized, Placebo-Controlled Study of the Effects of Denosumab for the Treatment of Men with Low Bone Mineral Density. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 3161-3169.	1.8	179
31	Quantitative ultrasound of the heel: Correlation with densitometric measurements at different skeletal sites. <i>Osteoporosis International</i> , 1994, 4, 42-47.	1.3	176
32	Discrepancies in normative data between Lunar and Hologic DXA systems. <i>Osteoporosis International</i> , 1996, 6, 432-436.	1.3	176
33	Observations following discontinuation of long-term denosumab therapy. <i>Osteoporosis International</i> , 2017, 28, 1723-1732.	1.3	174
34	Safety and Efficacy of Risedronate in Reducing Fracture Risk in Osteoporotic Women Aged 80 and Older: Implications for the Use of Antiresorptive Agents in the Old and Oldest Old. <i>Journal of the American Geriatrics Society</i> , 2004, 52, 1832-1839.	1.3	167
35	Dose-Response Relationships for Alendronate Treatment in Osteoporotic Elderly Women ¹ . <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 265-274.	1.8	165
36	Intravenous zoledronic acid 5Âmg in the treatment of postmenopausal women with low bone density previously treated with alendronate. <i>Bone</i> , 2007, 41, 122-128.	1.4	159

#	ARTICLE	IF	CITATIONS
37	Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 687-693.	3.1	156
38	Alendronate and Estrogen+Progestin in the Long-Term Prevention of Bone Loss: Four-Year Results from the Early Postmenopausal Intervention Cohort Study: A Randomized, Controlled Trial. <i>Annals of Internal Medicine</i> , 1999, 131, 935.	2.0	152
39	Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 1397-1406.	3.1	144
40	Osteoporosis in men: Epidemiology, diagnosis, prevention, and treatment. <i>Clinical Therapeutics</i> , 2004, 26, 15-28.	1.1	142
41	Serum 25-Hydroxyvitamin D Levels: Variability, Knowledge Gaps, and the Concept of a Desirable Range. <i>Journal of Bone and Mineral Research</i> , 2015, 30, 1119-1133.	3.1	138
42	Risedronate in the Treatment of Paget's Disease of Bone: An Open Label, Multicenter Study. <i>Journal of Bone and Mineral Research</i> , 1998, 13, 1032-1038.	3.1	135
43	Comparison of Weekly Treatment of Postmenopausal Osteoporosis with Alendronate Versus Risedronate Over Two Years. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 2631-2637.	1.8	135
44	Increments in Bone Mineral Density of the Lumbar Spine and Hip and Suppression of Bone Turnover Are Maintained after Discontinuation of Alendronate in Postmenopausal Women. <i>American Journal of Medicine</i> , 1997, 103, 291-297.	0.6	134
45	Bone density recovery after depot medroxyprogesterone acetate injectable contraception use. <i>Contraception</i> , 2008, 77, 67-76.	0.8	132
46	Effect of Denosumab on Bone Mineral Density and Biochemical Markers of Bone Turnover: Six-Year Results of a Phase 2 Clinical Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 394-402.	1.8	131
47	Enhanced precision with dual-energy x-ray absorptiometry. <i>Calcified Tissue International</i> , 1992, 51, 14-17.	1.5	128
48	Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 211-218.	3.1	124
49	Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial. <i>Osteoporosis International</i> , 2015, 26, 699-712.	1.3	121
50	Prevention of Bone Loss with Tibolone in Postmenopausal Women: Results of Two Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Studies. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 4717-4726.	1.8	118
51	Application of the 1994 WHO Classification to Populations Other Than Postmenopausal Caucasian Women: The 2005 ISCD Official Positions. <i>Journal of Clinical Densitometry</i> , 2006, 9, 22-30.	0.5	116
52	Automated evaluation of hip axis length for predicting hip fracture. <i>Journal of Bone and Mineral Research</i> , 1994, 9, 1065-1070.	3.1	111
53	Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 899-911.	5.5	111
54	Alendronate Improves Bone Mineral Density in Elderly Women with Osteoporosis Residing in Long-Term Care Facilities. <i>Annals of Internal Medicine</i> , 2002, 136, 742.	2.0	110

#	ARTICLE	IF	CITATIONS
55	Fine-Needle Aspiration Cytology in the Preoperative Diagnosis of Thyroid Nodules. <i>Annals of Internal Medicine</i> , 1977, 87, 265.	2.0	109
56	American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosisâ€” 2020 Update Executive Summary. <i>Endocrine Practice</i> , 2020, 26, 564-570.	1.1	108
57	Changes in bone density and turnover after alendronate or estrogen withdrawal. <i>Menopause</i> , 2004, 11, 622-630.	0.8	107
58	A 24-Month Study Evaluating the Efficacy and Safety of Denosumab for the Treatment of Men With Low Bone Mineral Density: Results From the ADAMO Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 1335-1342.	1.8	105
59	Quality control of DXA instruments in multicenter trials. <i>Osteoporosis International</i> , 1995, 5, 218-227.	1.3	103
60	Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. <i>Osteoporosis International</i> , 2013, 24, 227-235.	1.3	103
61	Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene. <i>Menopause</i> , 2006, 13, 377-386.	0.8	101
62	Zoledronic Acid for the Prevention of Bone Loss in Postmenopausal Women With Low Bone Mass. <i>Obstetrics and Gynecology</i> , 2009, 114, 999-1007.	1.2	101
63	The Incidence of Osteonecrosis of the Jaw in Patients Receiving 5 Milligrams of Zoledronic Acid. <i>Journal of the American Dental Association</i> , 2010, 141, 1365-1370.	0.7	99
64	Femoral and Vertebral Strength Improvements in Postmenopausal Women With Osteoporosis Treated With Denosumab. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 158-165.	3.1	98
65	Bone mineral density in women aged 25â€“35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation. <i>Contraception</i> , 2006, 74, 90-99.	0.8	96
66	Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 397-404.	3.1	96
67	Oral Daily Ibandronate Prevents Bone Loss in Early Postmenopausal Women Without Osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2003, 19, 11-18.	3.1	95
68	Femoral strength in osteoporotic women treated with teriparatide or alendronate. <i>Bone</i> , 2012, 50, 165-170.	1.4	93
69	Pins and Plaster Arenâ€™t Enough: A Call for the Evaluation and Treatment of Patients with Osteoporotic Fractures. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 3482-3486.	1.8	89
70	Efficacy and safety of risedronate 150Âµg once a month in the treatment of postmenopausal osteoporosis. <i>Bone</i> , 2008, 42, 36-42.	1.4	89
71	Alendronate in Early Postmenopausal Women: Effects on Bone Mass during Long-Term Treatment and after Withdrawal. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 1492-1497.	1.8	87
72	Effects of Atorvastatin on Bone in Postmenopausal Women with Dyslipidemia: A Double-Blind, Placebo-Controlled, Dose-Ranging Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 4671-4677.	1.8	85

#	ARTICLE	IF	CITATIONS
73	Cancel the denosumab holiday. Osteoporosis International, 2016, 27, 1677-1682.	1.3	81
74	Clinical utility of bone mass measurements in adults: Consensus of an international panel. Seminars in Arthritis and Rheumatism, 1996, 25, 361-372.	1.6	80
75	Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate. Osteoporosis International, 2011, 22, 1725-1735.	1.3	77
76	A multicenter study of the influence of fat and lean mass on bone mineral content: evidence for differences in their relative influence at major fracture sites. Early Postmenopausal Intervention Cohort (EPIC) Study Group. American Journal of Clinical Nutrition, 1996, 64, 354-360.	2.2	75
77	Prevention of Postmenopausal Bone Loss: Six-Year Results from the Early Postmenopausal Intervention Cohort Study. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 4879-4885.	1.8	75
78	Bone Mineral Density After Transitioning From Denosumab to Alendronate. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e255-e264.	1.8	73
79	Development and Validation of the Mini-Osteoporosis Quality of Life Questionnaire (OQLQ) in Osteoporotic Women with Back Pain due to Vertebral Fractures. Osteoporosis Quality of Life Study Group. Osteoporosis International, 1999, 10, 207-213.	1.3	72
80	Denosumab Rapidly Increases Cortical Bone in Key Locations of the Femur: A 3D Bone Mapping Study in Women With Osteoporosis. Journal of Bone and Mineral Research, 2015, 30, 46-54.	3.1	69
81	Role of RANKL inhibition in osteoporosis. Arthritis Research and Therapy, 2007, 9, S3.	1.6	66
82	Bisphosphonates. Endocrinology and Metabolism Clinics of North America, 2003, 32, 253-271.	1.2	62
83	Effects of risedronate on fracture risk in postmenopausal women with osteopenia. Osteoporosis International, 2008, 19, 681-686.	1.3	61
84	Denosumab Reduces Cortical Porosity of the Proximal Femoral Shaft in Postmenopausal Women With Osteoporosis. Journal of Bone and Mineral Research, 2016, 31, 1827-1834.	3.1	60
85	American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Postmenopausal Osteoporosis: Executive Summary of Recommendations. Endocrine Practice, 2010, 16, 1016-1019.	1.1	59
86	Improvements in hip trabecular, subcortical, and cortical density and mass in postmenopausal women with osteoporosis treated with denosumab. Bone, 2013, 56, 482-488.	1.4	59
87	Monthly dosing of 75Âmg risedronate on 2 consecutive days a month: efficacy and safety results. Osteoporosis International, 2008, 19, 1039-1045.	1.3	58
88	The relationship between bone mineral density and fracture risk. Current Osteoporosis Reports, 2005, 3, 57-63.	1.5	57
89	Sclerostin antibodies in osteoporosis: latest evidence and therapeutic potential. Therapeutic Advances in Musculoskeletal Disease, 2017, 9, 263-270.	1.2	56
90	Yearly zoledronic acid in postmenopausal osteoporosis. New England Journal of Medicine, 2007, 357, 712-3; author reply 714-5.	13.9	56

#	ARTICLE	IF	CITATIONS
91	The Long-Term Effect Of Specific Type II 5 α -Reductase Inhibition With Finasteride on Bone Mineral Density in Men: Results of a 4-Year Placebo Controlled Trial. <i>Journal of Urology</i> , 2002, 167, 2105-2108.	0.2	54
92	Creation of an Age-Adjusted, Dual-Energy X-ray Absorptiometryâ€Derived Trabecular Bone Score Curve for the Lumbar Spine in Non-Hispanic US White Women. <i>Journal of Clinical Densitometry</i> , 2014, 17, 314-319.	0.5	53
93	Romozosumab for the treatment of osteoporosis. <i>Osteoporosis and Sarcopenia</i> , 2018, 4, 11-15.	0.7	53
94	Prevention of Bone Loss with Tibolone in Postmenopausal Women: Results of Two Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Studies. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 4717-4726.	1.8	50
95	Denosumab Significantly Increases DXA BMD at Both Trabecular and Cortical Sites: Results From the FREEDOM Study. <i>Journal of Clinical Densitometry</i> , 2013, 16, 147-153.	0.5	49
96	Invasive Oral Procedures and Events in Postmenopausal Women With Osteoporosis Treated With Denosumab for Up to 10 Years. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2443-2452.	1.8	48
97	Tiludronate therapy for Paget's disease of bone. <i>Bone</i> , 1995, 17, S493-S496.	1.4	47
98	Comparison of proximal femur and vertebral body strength improvements in the FREEDOM trial using an alternative finite element methodology. <i>Bone</i> , 2015, 81, 122-130.	1.4	47
99	Bisphosphonates in osteoporosis: recent clinical experience. <i>Expert Opinion on Pharmacotherapy</i> , 2000, 1, 225-238.	0.9	45
100	Effects of Pioglitazone on Bone in Postmenopausal Women With Impaired Fasting Glucose or Impaired Glucose Tolerance: A Randomized, Double-Blind, Placebo-Controlled Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 4691-4701.	1.8	45
101	Efficacy and safety of a novel delayed-release risedronate 35 μ g once-a-week tablet. <i>Osteoporosis International</i> , 2012, 23, 267-276.	1.3	44
102	Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 μ g weekly for 2 \hat{A} years. <i>Osteoporosis International</i> , 2013, 24, 301-310.	1.3	42
103	The efficacy of 48-week oral ibandronate treatment in postmenopausal osteoporosis when taken 30 versus 60 minutes before breakfast. <i>Bone</i> , 2003, 32, 421-426.	1.4	37
104	Serum protein concentrations and bone mineral content in aging normal men. <i>American Journal of Clinical Nutrition</i> , 1987, 46, 614-621.	2.2	36
105	Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis. <i>Menopause</i> , 2013, 20, 130-137.	0.8	35
106	Assessment of Mortality in Patients Enrolled in a Risedronate Clinical Trial Program: A Retrospective Cohort Study. <i>Regulatory Toxicology and Pharmacology</i> , 2002, 35, 320-326.	1.3	34
107	Bone Mineral Density and Parathyroid Hormone as Independent Risk Factors for Mortality in Community-Dwelling Older Adults: A Population-Based Prospective Cohort Study in Brazil. The S \hat{A} o Paulo Ageing & Health (SPAH) Study. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 1146-1157.	3.1	34
108	Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis. <i>Osteoporosis International</i> , 2017, 28, 2967-2973.	1.3	34

#	ARTICLE	IF	CITATIONS
109	A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate. <i>Osteoporosis International</i> , 2006, 17, 159-166.	1.3	33
110	Evidence that increased calcium intake does not prevent early postmenopausal bone loss. <i>Clinical Therapeutics</i> , 1998, 20, 933-944.	1.1	31
111	Denosumab Densitometric Changes Assessed by Quantitative Computed Tomography at the Spine and Hip in Postmenopausal Women With Osteoporosis. <i>Journal of Clinical Densitometry</i> , 2013, 16, 250-256.	0.5	31
112	Effects of abaloparatide on bone mineral density and risk of fracture in postmenopausal women aged 80 years or older with osteoporosis. <i>Menopause</i> , 2018, 25, 767-771.	0.8	31
113	Blood pressure and calcium intake are related to bone density in adult males. <i>British Journal of Nutrition</i> , 1999, 81, 383-388.	1.2	29
114	Do current management strategies and guidelines adequately address fracture risk?. <i>Bone</i> , 2006, 38, 13-17.	1.4	29
115	Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss. <i>Bone</i> , 2009, 44, 418-422.	1.4	28
116	Prediction of Fracture Risk I: Bone Density. <i>American Journal of the Medical Sciences</i> , 1996, 312, 257-259.	0.4	28
117	Multisite Bone Ultrasound Measurement on North American Female Reference Population. <i>Journal of Clinical Densitometry</i> , 2001, 4, 239-248.	0.5	27
118	Emerging Therapies for Osteoporosis. <i>Endocrinology and Metabolism</i> , 2015, 30, 429.	1.3	27
119	Measurement of Body Composition in the Elderly: Dual Energy X-Ray Absorptiometry, Underwater Weighing, Bioelectrical Impedance Analysis, and Anthropometry. <i>Gerontology</i> , 1994, 40, 332-339.	1.4	26
120	Histomorphometric effects of calcium or calcium plus 25-hydroxyvitamin D3 therapy in senile osteoporosis. <i>Journal of Bone and Mineral Research</i> , 1989, 4, 81-88.	3.1	26
121	Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data. <i>Osteoporosis International</i> , 2013, 24, 293-299.	1.3	26
122	Using Osteoporosis Therapies in Combination. <i>Current Osteoporosis Reports</i> , 2017, 15, 343-352.	1.5	26
123	A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab. <i>Osteoporosis International</i> , 2020, 31, 2231-2241.	1.3	26
124	Skeletal responses to romosozumab after 12 months of denosumab. <i>JBMR Plus</i> , 2021, 5, e10512.	1.3	26
125	Therapy for Fracture Prevention. <i>JAMA - Journal of the American Medical Association</i> , 1999, 282, 687.	3.8	25
126	Role of bone-forming agents in the management of osteoporosis. <i>Aging Clinical and Experimental Research</i> , 2021, 33, 775-791.	1.4	25

#	ARTICLE	IF	CITATIONS
127	Treatment With Once-Weekly Alendronate 70 mg Compared With Once-Weekly Risedronate 35 mg in Women With Postmenopausal Osteoporosis: A Randomized Double-Blind Study. <i>Journal of Bone and Mineral Research</i> , 2005, 20, 141-151.	3.1	25
128	Prevention and management of osteoporosis. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2003, 17, 53-71.	2.2	24
129	Odanacatib in postmenopausal women with low bone mineral density: a review of current clinical evidence. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2013, 5, 199-209.	1.2	23
130	Osteoporosis Update From the 2010 Santa Fe Bone Symposium. <i>Journal of Clinical Densitometry</i> , 2011, 14, 1-21.	0.5	22
131	Calcium and cholecalciferol: effects of small supplements in normal men. <i>American Journal of Clinical Nutrition</i> , 1988, 48, 127-130.	2.2	21
132	Denosumab for the treatment of osteoporosis. <i>Osteoporosis and Sarcopenia</i> , 2017, 3, 8-17.	0.7	21
133	A Pooled Analysis of Fall Incidence From Placebo-Controlled Trials of Denosumab. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 1014-1021.	3.1	21
134	Densitometry of the radius using single and dual energy absorptiometry. <i>Calcified Tissue International</i> , 1994, 54, 208-211.	1.5	20
135	Reducing hip fracture risk with risedronate in elderly women with established osteoporosis. <i>Clinical Interventions in Aging</i> , 2009, 4, 445.	1.3	20
136	Assessing Fracture Risk and Effects of Osteoporosis Drugs: Bone Mineral Density and Beyond. <i>American Journal of Medicine</i> , 2009, 122, 992-997.	0.6	20
137	Western Osteoporosis Alliance Clinical Practice Series: Evaluating the Balance of Benefits and Risks of Long-Term Osteoporosis Therapies. <i>American Journal of Medicine</i> , 2017, 130, 862.e1-862.e7.	0.6	20
138	Current bone mineral density data on bisphosphonates in postmenopausal osteoporosis. <i>Bone</i> , 1996, 19, S195-S198.	1.4	19
139	Peritonitis in children receiving continuous ambulatory peritoneal dialysis. <i>Pediatric Infectious Disease Journal</i> , 1983, 2, 328-332.	1.1	19
140	FAMILIAL HYPERCHOLESTEROLAEMIA AND PRIMARY HYPOTHYROIDISM: COEXISTENCE OF BOTH DISORDERS IN A YOUNG WOMAN WITH SEVERE HYPERCHOLESTEROLAEMIA. <i>Clinical Endocrinology</i> , 1981, 14, 145-152.	1.2	17
141	Bisphosphonates. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2006, 50, 735-744.	1.3	17
142	Understanding and Communicating the Benefits and Risks of Denosumab, Raloxifene, and Teriparatide for the Treatment of Osteoporosis. <i>Journal of Clinical Densitometry</i> , 2014, 17, 490-495.	0.5	17
143	Osteopenia: To Treat or Not To Treat?. <i>Annals of Internal Medicine</i> , 2005, 142, 796.	2.0	16
144	Denosumab for Prevention of Fractures in Postmenopausal Women With Osteoporosis. <i>Obstetrical and Gynecological Survey</i> , 2009, 64, 805-807.	0.2	15

#	ARTICLE	IF	CITATIONS
145	Clinical utility of anti-sclerostin antibodies. <i>Bone</i> , 2017, 96, 3-7.	1.4	15
146	Western Osteoporosis Alliance Clinical Practice Series: Treat-to-Target for Osteoporosis. <i>American Journal of Medicine</i> , 2019, 132, e771-e777.	0.6	15
147	Osteoporosis Update From the 2012 Santa Fe Bone Symposium. <i>Journal of Clinical Densitometry</i> , 2013, 16, 584-600.	0.5	14
148	Controversies in Osteoporosis Management. <i>Clinical Obstetrics and Gynecology</i> , 2013, 56, 743-748.	0.6	14
149	Pharmacologic intervention for prevention of fractures in osteopenic and osteoporotic postmenopausal women: Systemic review and meta-analysis. <i>Bone Reports</i> , 2020, 13, 100729.	0.2	14
150	Incidence of Hip and Subtrochanteric/Femoral Shaft Fractures in Postmenopausal Women With Osteoporosis in the Phase 3 Long-Term Odanacatib Fracture Trial. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 1225-1234.	3.1	14
151	A National Random Survey of Bone Mineral Density Reporting in the United States. <i>Journal of Clinical Densitometry</i> , 2002, 5, 3-9.	0.5	13
152	To FRAX or not to FRAX. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 1240-1242.	3.1	13
153	Robust norms for neuropsychological tests of verbal episodic memory in Australian women.. <i>Neuropsychology</i> , 2019, 33, 581-595.	1.0	13
154	Discussion: Newer bisphosphonates in the treatment of paget's disease of bone: Where we are and where we want to go. <i>Journal of Bone and Mineral Research</i> , 1999, 14, 74-78.	3.1	12
155	Parathyroid Hormone for the Treatment of Osteoporosis. <i>Obstetrical and Gynecological Survey</i> , 2004, 59, 826-832.	0.2	12
156	Acute Parathyroid Hormone Secretory Dynamics: Hormone Secretion from Normal Primate and Adenomatous Human Tissue in Response to Changes in Extracellular Calcium Concentration*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1986, 62, 950-955.	1.8	11
157	An update on osteoporosis pathogenesis, diagnosis, and treatment. <i>Bone</i> , 2017, 98, 37.	1.4	11
158	Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with Abaloparatide. <i>Calcified Tissue International</i> , 2018, 102, 627-633.	1.5	11
159	History of risedronate. <i>Bone</i> , 2020, 137, 115407.	1.4	11
160	Review of risedronate in the treatment of osteoporosis. <i>Expert Opinion on Pharmacotherapy</i> , 2001, 2, 2011-2025.	0.9	10
161	Bone age as a correction factor for the analysis of trabecular bone score (TBS) in children. <i>Archives of Osteoporosis</i> , 2019, 14, 26.	1.0	10
162	Pathogenesis of osteoporotic hip fractures. <i>Clinical Cornerstone</i> , 2003, 5, S22-S29.	1.0	9

#	ARTICLE	IF	CITATIONS
163	A Novel Monthly Dosing Regimen of Risedronate for the Treatment of Postmenopausal Osteoporosis: 2-Year Data. <i>Calcified Tissue International</i> , 2013, 92, 59-67.	1.5	9
164	New management options for osteoporosis with emphasis on SERMs. <i>Climacteric</i> , 2015, 18, 56-61.	1.1	9
165	Treatment of Hyperthyroidism. <i>Annual Review of Medicine</i> , 1980, 31, 385-404.	5.0	8
166	Relation Between Body Composition and Biochemical Markers of Bone Turnover Among Early Postmenopausal Women. <i>Journal of Clinical Densitometry</i> , 2000, 3, 365-371.	0.5	7
167	Lebanese Guidelines for Osteoporosis Assessment and Treatment. <i>Journal of Clinical Densitometry</i> , 2005, 8, 148-163.	0.5	7
168	Bone safety with risedronate: histomorphometric studies at different dose levels and exposure. <i>Osteoporosis International</i> , 2015, 26, 327-337.	1.3	7
169	Osteoanabolic therapy for osteoporosis in women. <i>Climacteric</i> , 2022, 25, 60-66.	1.1	7
170	Use of Bone Densitometry Results for Decisions about Therapy for Osteoporosis. <i>Annals of Internal Medicine</i> , 1996, 125, 623.	2.0	7
171	Use of highly potent bisphosphonates in the treatment of osteoporosis. <i>Current Osteoporosis Reports</i> , 2003, 1, 116-122.	1.5	6
172	Bisphosphonate therapy: how long is long enough?. <i>Osteoporosis International</i> , 2015, 26, 1455-1457.	1.3	6
173	Bisphosphonates and Osteonecrosis of the Jaw. <i>Annals of Internal Medicine</i> , 2006, 145, 791.	2.0	6
174	Overdiagnosis and Overtreatment of Osteoporosis: A Wolf in Sheep's Clothing. <i>Journal of Bone and Mineral Research</i> , 2015, 30, 1754-1757.	3.1	5
175	Abaloparatide followed by alendronate in women ≥80 years with osteoporosis: post hoc analysis of ACTIVEExtend. <i>Menopause</i> , 2020, 27, 1137-1142.	0.8	5
176	Response to: Comment on: "Denosumab Rapidly Increases Cortical Bone in Key Locations of the Femur: A 3D Bone Mapping Study in Women With Osteoporosis" <i>Journal of Bone and Mineral Research</i> , 2015, 30, 1939-1940.	3.1	4
177	The clinical and epidemiologic consequences of redefining treatment criteria: who should be treated?. <i>Salud Publica De Mexico</i> , 2009, 51, s46-s51.	0.1	4
178	The role of osteoanabolic agents in the management of patients with osteoporosis. <i>Postgraduate Medicine</i> , 2022, 134, 541-551.	0.9	4
179	Mid-molecule parathyroid hormone assay comparison. <i>Clinical Biochemistry</i> , 1986, 19, 41-45.	0.8	3
180	Looking for answers in all the wrong places*. <i>Menopause</i> , 2007, 14, 7-9.	0.8	3

#	ARTICLE	IF	CITATIONS
181	Revisiting the prevention of bone loss at menopause. <i>Menopause</i> , 2012, 19, 1173-1175.	0.8	3
182	Bisphosphonate therapy: To stop or not to stop?. <i>BoneKEy Osteovision</i> , 2007, 4, 78-82.	0.6	3
183	Treating Paget's Disease of Bone. , 1992, 2, 22-28.		2
184	A randomized, double-blind, placebo-controlled study of a cathepsin-K inhibitor in the treatment of postmenopausal women with Low BMD: 18 month results. <i>Bone</i> , 2008, 42, S74.	1.4	2
185	Is altered bone health part of the metabolic syndrome?. <i>Menopause</i> , 2010, 17, 900-901.	0.8	2
186	Drug holidays in women treated for postmenopausal osteoporosis. <i>Menopause</i> , 2018, 25, 1152-1154.	0.8	2
187	Efficacy and Safety of Osteoporosis Treatment. , 2019, , 43-57.		2
188	Late skeletal effects of early menopause. <i>Menopause</i> , 2015, 22, 1027-1029.	0.8	1
189	Denosumab for the treatment of osteoporosis. , 2021, , 1737-1755.		1
190	How does raloxifene reduce fracture risk?. <i>Menopause</i> , 2002, 9, 306-308.	0.8	1
191	Bone Health and Hormonal Contraception. , 2014, , 287-306.		1
192	Use of highly potent bisphosphonates in the treatment of osteoporosis. <i>Current Osteoporosis Reports</i> , 2003, 1, 116-122.	1.5	1
193	Effects of E2/P4 oral capsules on bone turnover in women with vasomotor symptoms. <i>Menopause</i> , 2022, 29, 304-308.	0.8	1
194	Osteoporosis from the Perspective of an Endocrinologist. <i>Baylor University Medical Center Proceedings</i> , 1996, 9, 47-52.	0.2	0
195	Osteology: Further Debate. <i>Journal of Bone and Mineral Research</i> , 1999, 14, 1017-1017.	3.1	0
196	Risedronate Once A Week. <i>Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders</i> , 2003, 2, 421.	1.8	0
197	How to Interpret Surrogate Markers of Efficacy in Osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2005, 20, 1263-1264.	3.1	0
198	Who Should Be Screened: Who Should Be Treated?. , 2008, , 1449-1460.		0

#	ARTICLE	IF	CITATIONS
199	Denosumab for the Treatment of Osteoporosis. , 2013, , 1923-1934.		0
200	Re-Invigorating the Osteoporosis Message. Endocrine Practice, 2016, 22, 1130-1131.	1.1	0
201	REINVIGORATING THE OSTEOPOROSIS MESSAGE. Endocrine Practice, 2016, , .	1.1	0
202	Other Safety Concerns. , 2016, , 279-293.		0
203	ZOLEDRONOVAYa KISLOTA V PROFILAKTIKE POTERI KOSTNOY TKANI U zhENShchIN POSTMENOPAUZAL'NOGO VOZRATA S OSTEOPENIY. Osteoporosis and Bone Diseases, 2011, 14, 37-39.	0.3	0
204	Efficacy of odanacatib in postmenopausal women with osteoporosis: subgroup analyses of data from the phase 3 long-term odanacatib fracture trial (LOFT). Bone Abstracts, 0, , .	0.0	0